Search

everythinglearnresearchcommunity

for

Search:↓

Risankizumab effectively treats and maintains skin clearance in moderate-to-severe psoriasis.

Biologics and small molecules can effectively treat inflammatory nail disorders, but personalized treatment plans are important.

Infliximab can cause SAPHO syndrome, which may improve with Spesolimab and methotrexate.

New targeted therapies for psoriasis show promise but face challenges like side effects and treatment resistance.

Rezpegaldesleukin shows promise for treating severe alopecia areata.

Ixekizumab has known and some unexpected side effects.

Tildrakizumab showed limited effectiveness in treating chronic alopecia areata in a small group of patients.

Ixekizumab helps improve life quality, physical ability, and work performance in patients with psoriatic arthritis who haven't used biologic drugs before.

Ixekizumab is effective and safe for patients who did not improve with etanercept treatment for psoriasis.

Tildrakizumab significantly improved recalcitrant lichen planopilaris and frontal fibrosing alopecia.

A woman with a drug allergy to anakinra was successfully desensitized, allowing her to continue treatment without allergic reactions.

Ixekizumab effectively treats generalized pustular psoriasis.

Bimekizumab effectively treated a man's chronic beard hair loss.

Bimekizumab can improve scarring alopecia in severe psoriasis.

Switching from adalimumab to ixekizumab improved a patient's psoriasis and reversed hair whitening.

Guselkumab effectively treats skin reactions caused by adalimumab in certain conditions.

Nemolizumab improved both severe atopic dermatitis and alopecia areata in one patient.

Ixekizumab is safe for long-term use with low rates of major heart-related events.

Tildrakizumab may cause alopecia areata, but stopping it and using corticosteroids can regrow hair.

Ixekizumab effectively treated severe psoriasis and hair loss in a patient.

Ustekinumab successfully treated a man's resistant skin condition when other treatments failed.

Daclizumab may cause psoriasis-like skin problems in multiple sclerosis patients.

Ustekinumab significantly improved psoriasis, vitiligo, and alopecia areata in a patient.

Tildrakizumab significantly improved psoriasis symptoms and well-being over 52 weeks.

Ixekizumab may be an effective first treatment for a rare skin condition causing hair loss.

Ivarmacitinib significantly improved hair regrowth in severe alopecia areata after tofacitinib was less effective.

Canakinumab's effect on COVID-19 outcomes is unclear.

ASLAN004 was safe and well-tolerated, supporting further development for treating certain diseases.